BRAF and thyroid cancer: Given the critical role of RTK activation in the adaptive resistance of BRAFV600E-mutant cancers to BRAF inhibitors (67, 68, 69, 70), Sui et al. (71) hypothesized that the overexpression of NG2, commonly observed in advanced thyroid cancers, promotes resistance to BRAF inhibitors in BRAFV600E-mutant thyroid cancers.